Abstract
Chemoresistant mechanisms in T-cell acute lymphoblastic leukemia (T-ALL) patients are not clarified. The apoptotic signaling mediated by receptor of activated C kinase 1 (Rack1), protein kinase C (PKC) and FEM1 homolog b (FEM1b) was investigated in two T-ALL-derived cell lines (Jurkat and CCRF-CEM) following treatment with chemotherapy drugs vincristine and prednisone. Serum starvation or chemotherapeutic drugs significantly reduced Rack1 level and PKC activation, while promoted cellular apoptosis in both cell lines. Rack1 overexpression protected T-ALL cell against starvation or chemotherapeutic drug-induced apoptosis. Moreover, Rack1 overexpression reduced the level of cytochrome c and active caspase 3 as well as FEM1b and apoptotic protease activating factor-1 (Apaf-1), and inhibited induction of cellular apoptosis in chemotherapeutic drug-treated Jurkat cell. Interaction of Rack1 and PKCα, not PKCβ, was detected in both cell lines. Of note, Rack1 overexpression abrogated reduction of PKC kinase activity in chemotherapeutic drug-treated T-ALL cell. PKC kinase inhibitor Go6976 or siPKCα inhibited downregulation of FEM1b and/or Apaf-1, and thus increased cellular apoptosis in Rack1-overexpressed T-ALL cell receiving chemotherapeutic drugs. Accordingly, our data provided evidence that increased Rack1-mediated upregulation of PKC kinase activity may be responsible for the development of chemoresistance in T-ALL-derived cell line potentially by reducing FEM1b and Apaf-1 level.
Similar content being viewed by others
Introduction
Acute lymphoblastic leukemia (ALL), the most common cancer among children, typically presents with pallor and fatigue from anemia, bruising or bleeding due to thrombocytopenia, and infection caused by neutropenia1. Despite ALL is now curable in most of cases due to the huge improvements in the efficacy of chemotherapeutic drugs such as gluococorticoid (prednisone or dexamethasone) and vincristine sulfate, a higher frequency of chemotherapy resistance (chemoresistance) thus leading to treatment failure and early relapse still occurs in patients with T cell ALL, one high-risk ALL subtype2. Recently, activation of various signaling pathways such as Notch1, the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR), and BRD4/MYC has been found in T-ALL3. Nevertheless, the mechanisms by which ALL patients develop chemotherapy resistance are not completely elucidated, which limits advances and discoveries of new targeted therapies for this disease.
Receptor of activated C kinase 1 (Rack1), a highly conserved intracellular adaptor protein, is elevated in a variety of cancers such as breast cancer, glioma, hepatocellular carcinoma cell, non-small-cell lung cancer, and pulmonary adenocarcinoma4. In hepatocellular carcinoma cell, Rack1 promoted cellular proliferation through enhancing MKK7/JNK5 and PI3K/Rac1 activities6. In addition, nuclear Rack1 may interact with PKCβII (protein kinase C βII) thus promoting the phosphorylation of eIF4E and leading to preferential translation of the potent factors involved in growth, such as cycling D1 and Myc7. In colon cancer cells, Rack1 inhibits apoptosis by directly interacting with FEM1 homolog b (FEM1b), an intracellular pro-apoptotic protein, and thus promoting its ubiquitination and degradation, while downregulation of Rack1 led to FEM1b-mediated apoptosis8. Just recently, it was reported that Rack1 promoted proliferation of THP-1 cell, one acute myeloid leukemia (AML) cell line, by enhancing glycogen synthase kinase 3β (GSK3β) activity through de-phosphorylation at Ser9, whereas Rack1 knockdown did not enhance phosphorylation of GSK3β in THP1 cells, indicating that other mechanisms might be involved9.
Rack1 was firstly identified as one anchoring protein for PKC10. PKC, a family of serine/threonine protein kinase, is involved in regulating diverse cellular functions, including proliferation, differentiation, and apoptosis by controlling the function of other proteins through the phosphorylation of hydroxyl groups of serine and threonine on these proteins11. The PKC family is divided into three subgroups based on their second messenger requirements: the classical isoforms (α, βI, βII, and γ) that are dependent upon Ca2+ and diacylglycerol (DAG) for their activation, the novel isoforms (δ, ε, η, θ, and μ) that require DAG, but do not depend upon Ca2+, and the atypical isoforms (ζ and ι/λ) that require neither DAG nor Ca2+ for activation11. Rack1 could serve as a receptor for activated PKCβII and other PKC isoforms, including PKCδ and PKCμ12,13,14. The binding of Rack1 to PKC leads to an increase in kinase activity12, and Rack1 is also thought to shuttle activated PKC to its correct cellular location15. In the ALL-derived cell line REH, overexpression of PKCα was found to suppress mitochondrial protein phosphatase 2A (PP2A) activity while promote chemotherapy resistance against the drug etoposide16.
However, it is still unclear if Rack1 is involved in chemoresistance in T-ALL. This study investigated the function of Rack1, PKC, and FEM1b-mediated apoptotic signaling during the process of vincristine sulfate or prednisone-induced apoptosis in two human T-ALL-derived cell lines. We provide evidence that Rack1 overexpression upregulated PKCα activity, which may be responsible for chemoresistance development in T-ALL-derived cell line by at least partially reducing the level of FEM1b, Apaf-1 and caspase 3.
Results
Overexpression of Rack1 inhibits starvation-induced apoptosis in T-ALL-derived cell line
Receptor for activated protein kinase C1 (Rack1), plays a central role in the intracellular signaling pathways that lead to apoptosis in T cells17. In the present study, the expression level of Rack1 was investigated in serum starvation-induced apoptosis of the human T-ALL-derived Jurkat cell line. As compared with non-starved cell, the percentage of apoptotic cell was significantly increased starting at day 1 (6.27 ± 0.39 vs. 2.342 ± 0.330; p < 0.001) and persisting to day 2 (11.26 ± 1.211 vs. 3.28 ± 0.202; p < 0.001) and day 3 (16.64 ± 0.858 vs. 3.71 ± 0.108; p < 0.001) in serum-starved Jurkat cell (Fig. 1a). Additionally, the MTT assay shows that compared to non-starved cells, the proliferative ability was remarkably decreased at day 2 (0.293 ± 0.060 vs. 0.487 ± 0.061; p < 0.01) and day 3 (0.290 ± 0.036 vs. 0.650 ± 0.056; p < 0.001) in serum-starved Jurkat cell (Fig. 1b). Rack1 expression level was then assessed using real time PCR and Western blot assay in serum-starved Jurkat cell. The fold change of Rack1 both at mRNA and protein level was significantly downregulated (p < 0.01) at day 2 (mRNA: 0.65 ± 0.12; protein: 0.52 ± 0.14) and day 3 (mRNA: 0.48 ± 0.08; protein: 0.32 ± 0.07) following serum starvation (Fig. 1c,d).
In serum-starved CCRF-CEM cell, another T-ALL-derived cell line, the apoptotic level was also obviously higher at day 2 (9.47 ± 0.67 vs. 2.95 ± 0.51; p < 0.01) and day 3 (12.21 ± 0.94 vs. 3.10 ± 0.53; p < 0.001) compared to non-starved cell (Supplemental Fig. 1a). Consistently, MTT assay shows that the proliferative ability was decreased significantly at day 2 (0.34 ± 0.06 vs. 0.52 ± 0.07; p < 0.05) and day 3 (0.37 ± 0.04 vs. 0.65 ± 0.05; p < 0.01) following serum starvation in CCRF-CEM cell (Supplemental Fig. 1b). Following serum starvation, Rack1 mRNA and protein level was also reduced significantly (p < 0.05) starting at day 1 in CCRF-CEM cell (Supplemental Fig. 1c,d). These results suggest that reduction of Rack1 expression level may be related to serum starvation-induced apoptosis in T-ALL-derived cell line.
By stably transfecting pcDNA3.1-human Rack1, we established a Rack1-overexpressed Jurkat cell clone (JurkatpRack1), and empty vector transfected cell (JurkatpEmp) was used as control. Overexpression of Rack1 was detected at both mRNA and protein level in JurkatpRack1 cell (Fig. 2a,b). Following serum starvation, the percentage of apoptotic cell was obviously lower at day 2 (6.4 ± 1.01 vs. 10.5 ± 2.62; p < 0.01) and day 3 (8.7 ± 1.38 vs. 16.5 ± 3.62; p < 0.001) in JurkatpRack1 cell compared to JurkatpEmp (Fig. 2c), implying that upregulation of Rack1 may protect Jurkat cell against serum starvation-induced apoptosis. To further verify the role of Rack1 in induction of apoptosis, we successfully downregulated Rack1 level in both Jurkat and CCRF-CEM cell by applying the specific siRNA (Fig. 2d; Supplemental Fig. 1e), and found that cellular apoptosis level was increased significantly (p < 0.01) at 48 h, particularly at 96 h following Rack1 knockdown (Fig. 2e; Supplemental Fig. 1f).
Overexpression of Rack1 protects Jurkat cell against chemotherapy drug-induced apoptosis
Vincristine sulfate, a chemotherapy medication, is widely used to treat a number of types of cancer including ALL by induction of cancer cell apoptosis2. Prednisone, a synthetic corticosteroid drug, is particularly effective as an immunosuppressant drug that causes massive cell death and cell cycle arrest in malignant cells, and is therefore included in almost all treatment protocols for lymphoid malignancies, particularly children ALL2. Here, the effects of Rack1 expression level on the efficacy of vincristine and prednisone were studied in Jurkat cell. The treatment with vincristine (1 ng/ml) or prednisone (0.5 μM) led to a time-dependent increase of cellular apoptosis in both JurkatpRack1 and JurkatpEmp cell (Fig. 3a). However, following treatment with vincristine (Vin: 1 ng/ml) or prednisone (Pre: 0.5 μM), the percentage of apoptotic cell was obviously lower at day 2 (Vin: 6.8 ± 1.37 vs. 12.3 ± 2.56, p < 0.05; Pre: 7.9 ± 2.54 vs. 11.3 ± 3.28, p < 0.05) and day 3 (Vin: 9.2 ± 3.17 vs.18.2 ± 4.02, p < 0.05; Pre: 10.1 ± 3.88 vs. 15.6 ± 4.02, p < 0.05) in JurkatpRack1 cell compared to JurkatpEmp (Fig. 3a). MTT assay shows that the proliferative ability of either wild type Jurkat or JurkatpEmp cell was decreased significantly (p < 0.01) at day 2 following the two chemotherapeutic drugs administration, while Rack1 overexpression obviously (p < 0.05) abrogated reduction of proliferative ability induced by chemotherapeutic drug (Fig. 3b).
The level of apoptotic proteins including cytochrome c, caspase 9 and caspase 3 was evaluated using immunoblot assay in Rack1-overexpressed Jurkat cell following a two-day treatment with vincristine or prednisone. The application of vincristine (1 ng/ml) or prednisone (0.5 μM) significantly (p < 0.01) increased the level of cytochrome c as well as activated caspase 9 and activated caspase 3 in both JurkatpRack1 and JurkatpEmp cell (Fig. 3c). Nevertheless, the level of all the three apoptotic proteins was obviously lower (p < 0.05) in JurkatpRack1 cell compared to JurkatpEmp (Fig. 3c). We further explored the role of these apoptotic proteins in promoting Jurkat cell apoptosis by applying a pan caspase family inhibitor Z-VAD-FMK (VAD) at different concentrations (2.5, 5, and 10 μM, respectively). Our results show that VAD administration obviously (p < 0.05) decreased the level of activated caspase 3 in a dose-dependent manner in Jurkat cell (Fig. 3d). The application of vincristine (1 ng/ml) in the presence of VAD also significantly (p < 0.05) decreased cellular apoptosis level in JurkatpEmp cell, particularly in JurkatpRack1 cell (Fig. 3e). Our findings demonstrated that Rack1 overexpression protected Jurkat cell against chemotherapeutic drug-induced apoptosis possibly through downregulating these apoptotic proteins. Hence, upregulation of Rack1 may decrease the therapeutic ability of vincristine and prednisone in T-ALL patients.
Induction of FEM1 homolog b (FEM1b) is involved in apoptosis as a pro-apoptotic protein that may interact with the apoptosis-inducing proteins such as Fas, tumor necrosis factor receptor-1 (TNFR1), and apoptotic protease activating factor-1 (Apaf-1)18,19. In this study, the abundance of FEM1b and Apaf-1 mRNA was evaluated using real time PCR following treatment with vincristine (1 ng/ml) or prednisone (0.5 μM) in JurkatpEmp and JurkatpRack1 cell. Vincristine and prednisone significantly (P < 0.05) increased the mRNA level of FEM1b and Apaf-1 at day 2 and 3 in both JurkatpEmp and JurkatpRack1 cell (Fig. 4a). In comparison with JurkatpEmp, FEM1b and Apaf-1 mRNA level was obviously lower (p < 0.05) at day 2 and 3 in JurkatpRack1 cell (Fig. 4a). The protein abundance of FEM1b and Apaf-1 was further explored using immunoblot assay 2 days after treatment with vincristine or prednisone. Compared to non-treated cell, FEM1b and Apaf-1 level was increased significantly (P < 0.05) following vincristine or prednisone treatment in both JurkatpEmp and JurkatpRack1 cell (Fig. 4b). Compared to JurkatpEmp, the level of FEM1b and Apaf-1 was obviously lower (P < 0.05) in vincristine or prednisone-treated JurkatpRack1 cell (Fig. 4b). Of note, the reduction in upregulation of FEM1b protein level was more pronounced upon treatment with vincristine than prednisone in JurkatpRack1 cell. These data indicate that Rack1 overexpression abrogated upregulation of FEM1b and Apaf-1 in chemotherapeutic drug-treated Jurkat cell.
Chemotherapeutic drug decreased Rack1 level and PKC kinase activity in T-ALL-derived cell line
Expression level of Rack1 was investigated in chemotherapeutic drug-treated T-ALL cell line. Immunoblot assay and real time PCR show that vincristine (1 ng/ml) or prednisone (0.5 μM) significantly (P < 0.05) decreased Rack1 expression at both mRNA and protein level in a time-dependent manner (Fig. 5a,b). In CCRF-CEM cell, reduction of Rack1 whereas increase of FEM1b, Apaf-1 and activated caspase 3 were also detected in a time-dependent manner following vincristine (1 ng/ml) treatment (Supplemental Fig. 2a,b). Notably, we assessed Rack1 expression level in primary PBMCs isolated from child T-ALL patients. Our preliminary results showed that Rack1 level was significantly (p < 0.05) higher in newly diagnosed T-ALL patients than healthy control, while there was no obvious difference between T-ALL in remission and healthy control (Fig. 5c). Rack1 was firstly described as a PKCβII anchoring protein, and was extensively studied in relation to PKC signaling13,14,15. PKC plays important role in regulating vasculogenesis and cellular proliferation, and activation of PKC promotes tumor growth by enhancing various cellular signaling pathways11. Here, the PKC kinase activity was assessed using PKC Kinase Activity Detection Kit. The application of prednisone (0.5 μM) and vincristine (1 ng/ml) significantly decreased (P < 0.05) the PKC kinase activity in a time-dependent fashion (Fig. 5d). These results suggest that there may be a potential correlation between Rack1 level and PKC kinase activity in T-ALL-derived cell.
Inhibition of PKC kinase activity decreased Rack1 overexpression-induced chemoresistance in T-ALL cell line
The effect of Rack1 level on PKC kinase activity was further evaluated in this study. Compared to day 0, vincristine (1 ng/ml) significantly (p < 0.05) reduced PKC kinase activity since day 1, and prednisone (0.5 μM) significantly (p < 0.05) reduced at day 2 and 3, in both JurkatpEmp and JurkatpRack1 cell (Fig. 6a). Of note, the level of PKC kinase activity was obviously (p < 0.05) higher upon treatment with vincristine (since day 1) or prednisone (at day 2 and 3) in JurkatpRack1 cell compared to JurkatpEmp (Fig. 6a), suggesting that Rack1 overexpression abrogated reduction of PKC kinase activity following chemotherapeutic drug treatment. To identify the specific PKC isoform that potentially interacts with Rack1, we performed immunoprecipitation assay in both Jurkat and CCRF-CEM cell lines. We found that Rack1 bound to PKCα, not PKCβ (Fig. 6b; Supplemental Fig. 2c). At the concentration of 1 μM, Go6976, a potent PKCα/β inhibitor, significantly (p < 0.05) reduced PKC kinase activity in both JurkatpEmp and JurkatpRack1 cells, especially in the presence of prednisone or vincristine (Fig. 6c). The relationship between PKC kinase activity and FEM1b level was then assessed by using Go6976. The application of Go6976 in either Jurkat or JurkatpEmp cell showed no effects on FEM1b and Apaf-1 protein level (Fig. 6d). Vincristine remarkably increased FEM1b and Apaf-1 level in JurkatpEmp cell, but not in JurkatpRack1 (Fig. 6e). Nevertheless, the application of Go6976 increased FEM1b and Apaf-1 expression in JurkatpRack1 cell following vincristine treatment (Fig. 6e). At day 2 following vincristine treatment, the percentage of apoptotic cell was significantly (p < 0.01) increased in JurkatpEmp cell, but not in JurkatpRack1 (Fig. 6f), indicating that Rack1 overexpression abrogated induction of apoptosis in vincristine-treated Jurkat cell. However, vincristine in the presence of Go6976 significantly (p < 0.05) induced cellular apoptosis in JurkatpRack1 cell (Fig. 6f). We also transiently overexpressed Rack1 in CCRF-CEM cell (Supplemental Fig. 2d). Although vincristine significantly (p < 0.01) induced apoptosis in CCRF-CEM cell regardless of Rack overexpression, the percentage of apoptotic cell was obviously (p < 0.05) lower in Rack1-overexpressed CCRF-CEM cell compared to wild type (Supplemental Fig. 2e). It should be noted that the combination of Go6976 and vincristine significantly (p < 0.05) increased apoptosis level in JurkatpRack1 cell (Supplemental Fig. 2e). Additionally, we also found that vincristine significantly (p < 0.05) reduced PKC kinase activity in both wild type and Rack1-overexpressed CCRF-CEM cell. The level of PKC activity was obviously (p < 0.05) higher upon treatment with vincristine in Rack1-overexpressed CCRF-CEM cell compared to wild type (Supplemental Fig. 2f). Further, the role of PKCα was investigated in vincristine-treated JurkatRack1 cell expressing siPKCα. We showed that 3 days following siPKCα transfection, expression of PKCα was successfully decreased in vincristine-treated JurkatRack1 cell (Fig. 6g). Vincristine remarkably increased Apaf-1 level in JurkatpEmp cell, but not in JurkatpRack1 cell (Fig. 6g). Nevertheless, siPKCα increased Apaf-1 expression in vincristine-treated JurkatpRack1 cell (Fig. 6g). Vincristine significantly (p < 0.01) increased the percentage of apoptotic cell in JurkatpEmp cell, which was decreased by Rack1 overexpression (Fig. 6h). However, in vincristine-treated JurkatpRack1 cell, the percentage of apoptotic cell was higher in the presence of siPKCα than siControl (Fig. 6h).
Therefore, our findings indicate that following treatment with chemotherapeutic drugs, Rack1 overexpression abrogated reduction of PKC kinase activity and thus decreased the FEM1b-Apaf1-caspase 3 apoptotic signaling, finally leading to reduction of apoptosis and development of chemoresistance in T-ALL derived cell line.
Discussion
Rack1, the WD-40 family protein, has a highly conserved WD-40 repeats involved in protein-protein interactions4. Aberrant Rack1 expression has been found in many cancers4. It was firstly described that Rack1 overexpression could produce resistance to dexamethasone and ultraviolet-induced apoptosis in mouse thymoma-derived cell line W7.220. Goniothalamin, a plant styryllactone, induces cytotoxicity via apoptotic cell death in a variety of cancer cell lines including leukemia HL-60, Jurkat and CEM-SS20. Although it was further reported that overexpression of Rack1 resulted in inhibition of goniothalamin-induced cell death in both W7.2 and Jurkat cells21, the underlying mechanisms are not fully understood.
In the current study, we explored the role of Rack1 level and the potential signaling pathway in chemotherapeutic drug-induced apoptosis of two T-ALL derived cell lines. We found that downregulation of Rack1 by using siRNA promoted apoptosis in both Jurkat and CCRF-CEM cells (Fig. 2d,e; Supplemental Fig. 1e,f). Moreover, time-dependent reduction of Rack1 level was also detected during the process of serum starvation-induced apoptosis (Fig. 1a–d; Supplemental Fig. 1a–d). Nevertheless, Rack1 overexpression protected Jurkat cell against serum starvation-induced apoptosis (Fig. 2a–c). These findings provide direct evidence that Rack1 plays a crucial role in regulating apoptosis, and upregulation of Rack1 may lead to resistance to death induction in T-ALL cell. In consistent, it was reported that Rack1 promoted proliferation of acute myeloid leukemia (AML)-derived cell line THP-19.
Prednisone or dexamethasone and vincristine are commonly used as the basic therapies for children with ALL. Resistance to these chemotherapeutic drugs frequently occurs in children ALL, particularly in T-ALL, one high-risk subtype2. In Jurkat and/or CCRF-CEM cell, we found that vincristine (1 ng/ml) and prednisone (0.5 μM) significantly decreased Rack1 expression level in a time-dependent manner (Fig. 5a,b; Supplemental Fig. 2a), and resulted in induction of cell death and inhibition of cell proliferation (Fig. 3a,b; Supplemental Fig. 2e). Similar as in serum-starvation condition, Rack1 overexpression protected T-ALL cell against vincristine or prednisone-induced apoptosis increase and/or proliferation inhibition (Fig. 3a,b; Supplemental Fig. 2e). The activation of caspase is a crucial step in initiating apoptosis21. The released cytochrome c from mitochondria promotes caspase 9 activation, which then activates downstream caspase proteins such as caspase 321. In this study, Rack1 overexpression inhibited the increase of cytochrome c as well as the activated caspase 9 and caspase 3 in vincristine- or prednisone-treated Jurkat cell (Fig. 3c). As such, overproduced Rack1 may decrease the therapeutic efficacy of vincristine and prednisone by preventing cell death at least partially via downregulation of these apoptotic proteins. This was supported by the finding from caspase inhibition assay that caspase inhibitor Z-VAD-FMK decreased vincristine (1 ng/ml)-induced apoptosis level in JurkatpEmp cell, particullay in JurkatpRack1 cell (Fig. 3d,e). Hence, these findings suggest that overproduced Rack1 may be a major factor responsible for chemoresistance in children with T-ALL.
In apoptosis-resistant SW620 cell, derived from a primary colon cancer, Rack1 overexpression led to downregulation of FEM1b, an intracellular pro-apoptotic protein, by promoting its ubiquitination8. FEM1b is highly conserved in mammals, and increased FEM1b could induce apoptosis in a variety of mammalian cells including cancer cells18,19. As a mediator, FEM1b interacts with both upstream and downstream components of the apoptosis machinery. The key downstream target of FEM1b is apoptotic protease activating factor-1 (Apaf-1), a critical element in the induction of apoptosis18,19. In this study, expression of FEM1b and Apaf-1 was assessed in Jurkat and CCRF-CEM cell following treatment with vincristine (1 ng/ml) or prednisone (0.5 μM). Our data show that vincristine or prednisone treatment significantly increased the levels of FEM1b and Apaf-1 (Fig. 4; Supplemental Fig. 2a). However, Rack1 overexpression abrogated upregulation of FEM1b and Apaf-1 in vincristine- or prednisone-treated Jurkat cell (Fig. 4). Accordingly, these findings revealed a potential relationship between Rack1 and FEM1b in T-ALL cell line.
Rack1 was firstly described as scaffolding or anchoring protein for PKCβII10. Activation of PKC promotes tumor growth by enhancing various signaling pathways11. Here, the application of prednisone (0.5 μM) or vincristine (1 ng/ml) remarkably decreased the activity of PKC in a time-dependent fashion in Jurkat cell (Fig. 5d), which was partially inhibited by Rack1 overexpression (Fig. 6a). To identify the specific PKC isoform that interacts with Rack1, we performed immunoprecipitation assay in Rack1-overexpressed Jurkat and CCRF-CEM cell. As expected, we found that Rack1 interacted with PKCα, not PKCβ (Fig. 6b; Supplemental Fig. 2c). Similarly, it was reported that the ALL-derived cell line REH that over-expresses PKCα showed resistance to against the drug etoposide16. Go6976, a potent PKCα/β inhibitor, mainly suppressing PKCα activation at the concentration of 1 μM, dramatically reduced PKC kinase activity in both Jurkat and CCRF-CEM cells (Fig. 6c; Supplemental Fig. 2f). The relationship between PKC activation level and FEM1b expression was also assessed in the current study. Rack1 overexpression abolished increase of FEM1b and Apaf-1 in vincristine-treated Jurkat cell (Fig. 6e). However, the presence of Go6976 significantly increased FEM1b and Apaf-1 expression in JurkatpRack1 cell receiving vincristine (Fig. 6e). Our results indicated a key role of PKCα activation in downregulating FEM1b level in Jurkat cell. In malignant colon cancer cells, it has been found that association of Rack1 with FEM1b mediates downregulation of FEM1b protein level by promoting ubiquitination of FEM1b8. Based on our current findings, we proposed that Rack1 overexpression downregulated FEM1b level possibly through activating PKCα and thus inducing traffic of PKCα to proteasome for degradation. Notably, the presence of Go6976 remarkably increased the effect of vincristine on induction of apoptosis in Rack1 overexpressed Jurkat and CCRF-CEM cell (Fig. 6f; Supplemental Fig. 2e). Similarly, siPKCα increased Apaf-1 expression in vincristine-treated JurkatpRack1 cell (Fig. 6g). In vincristine-treated JurkatpRack1 cell, the apoptotic cell percent was obviously higher in the presence of siPKCα than siControl (Fig. 6h). Accordingly, our data demonstrated that inhibition of PKCα activity abolished Rack1 overexpression-induced chemoresistance in T-ALL-derived cell line. Carlet et al. explored transcriptome profiling of glucocorticoid (GC) resistant and sensitive T-ALL cells CCRF-CEM-C7H2 during GC treatment and corresponding carrier control samples (GEO DataSets, GDS4203; Reference Series, GSE22152). We analyzed this data set (Supplemental Fig. 3). Although Apaf-1 level showed no difference between GC resistant and sensitive clones, dexamethasone significantly increased Apaf-1 expression in GC sensitive clones. Unfortunately, differential expression of PKCα was not detected among the four groups. Unexpectedly, Rack1 level was significantly lower in GC resistant clones than GC sensitive clones, and dexamethasone showed no effects on Rack1 level in both GC resistant and sensitive clones. Therefore, Rack1-involved signaling pathway need be investigated in other chemorsesistant T-ALL cells. Still interestingly, our preliminary data showed that in comparison to healthy samples, Rack1 mRNA level was obviously higher in newly diagnosed child T-ALL patients, but not in T-ALL remission patients (Fig. 5c).
Taken together, although our findings suggest that targeting PKC, particular PKCα, may provide a novel therapeutic approach to overcome Rack1 overexpression-induced chemoresistance in T-ALL cells, the role of Rack1 and PKCα-related signaling should be further studied and validated in a large amount of T-ALL patients with various responses to chemotherapy and the age-matched healthy controls.
Materials and Methods
Antibodies
The following primary antibodies were used in this study: rabbit anti-Rack1 and mouse anti-FEM1b antibodies (Abcam), mouse anti-caspase 9 antibody (Cell Signaling), rabbit anti-active caspase 9 (Abcam), mouse anti-caspase 3 and rabbit anti-active caspase 3 antibodies (Abcam), rabbit anti-cytochrome c (Santa Cruz), mouse anti-β-actin or GAPDH, and rabbit anti-Apaf-1 antibodies (Sigma), and mouse anti-PKCα or PKCβ antibody (Santa Cruz).
Cell culture and treatment
The human T-ALL cell lines Jurkat (TIB-152; ATCC) and CCRF-CEM (CCL-119; ATCC) were cultured in RPMI1640 medium containing 10% fetal calf serum (Gibco), 10 mM HEPES, and 100U/ml penicillin/streptomycin.
To overexpress human Rack1, the whole coding sequences of Rack1 (NM_006098.4) were amplified, and cloned into pcDNA3.1myc/His/Neo between HindIII and NotI using the primers 5′-aagcttatgactgagcagatgaccc-3′ and 5′-gcggccgcgcgtgtgccaatggtcacc-3′. The human Jurkat cells were transfected with pcDNA3.1-Rack1 (pRack1) or pcDNA3.1 vector as empty control (pEmp) using the NucleofectorTM device according to the manufacturer’s instructions (Lonza), and cultured for 48 h. Thereafter, neomycin/G418 was added at the final concentration of 800 μg/ml to develop the stable Rack1-overexpressed Jurkat cell clone.
Rack1 knockdown was performed by introducing short interference RNA (siRNA) specifically targeted to human Rack1 (5′-aagctgaagaccaaccaca-3′)22. To knockdown PKCα, siRNA-PKCα expressing plasmid vector was constructed using the pcDNA-HU6 vector (Zhongshan Yingzhi). The validated sequence of siPKCα for human PKCα gene knockdown is 5′-gcgtcctgttgtatgaaat-3′corresponding to the coding regions 492 to 510 (NM_002737)23. To explore the effects of chemotherapeutic drugs, the Jurkat cells with or without Rack1 overexpression were treated for indicated time periods with vincristine sulfate (1 ng/ml; Sigma) or prednisone (0.5 μM; Sigma) in combination with PKCα inhibitor Go6976 (1 μM; Sigma) or a pan caspase inhibitor Z-VAD-FMK (2.5, 5.0, and 10 μM, respectively; Sigma).
Proliferation assay
The MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide] assay was used for determination of cellular proliferative ability. Briefly, 1 × 105 cells each well were seeded in duplicates to 96-well plate in 100 μl fresh media, then 10 μl of 12 mM of MTT (Sigma) was added and incubated at 37 °C for 2 h. All solution was removed by centrifugation. Then, 50 μl of DMSO was added and incubated at 37 °C for 10 min. The absorbance was read at 450 nm using a microplate reader, and the value of OD 450 was used to compare the proliferative ability.
Apoptosis assay
Cellular apoptosis was measured by staining with FITC-Annexin V and propidium iodide (Invitrogen). Briefly, Rack1-overespressed, serum starved, or chemotherapeutic drug treated cells were collected, and 1 × 106 cells/ml was resuspended in calcium/magnesium free Dulbecco’s phosphate-buffered saline (DPBS). The 100 μl was diluted in duplicates in 1x Annexin-binding buffer. Then, 5 μl of FITC-Annexin V and 1 μl of the 100 μg/ml of propidium iodide were added and incubated at room temperature for 15 min. Finally, 400 μl of 1x Annexin-binding buffer was added, and flow cytometry was performed to measure the fluorescence at the emission of 530 nm and 575 nm. The percentage of apoptotic cells (only showing green fluorescence) over total cells was used for statistical analysis.
Clinical samples and PBMCs isolation
Blood was collected in a heparin anticoagulation tube from 9 children T-ALL patients including 5 newly diagnosed (range of age: 2.5–14, media age: 5.5 years) and 4 remissions (range of age: 4–11, media age: 7 years), and 8 healthy controls (range of age: 7–16, media age: 10.5 years). The T-ALL was diagnosed according to the criteria of WHO Diagnosis and Classification of ALL (2008). Informed consent was signed by the guardians of all participants. This study was approved by the Ethics Review Committee of Jilin University First Hospital, and all the following experiments and methods with human samples including Peripheral blood mononuclear cells (PBMCs) isolation, RNA extraction and real time RT-PCR were performed in accordance with the relevant guidelines and regulations.
PBMCs were isolated from patients and healthy controls using typical procedure density gradient centrifugation. Briefly, 2 ml of blood was diluted with 2 volumes of PBS, and mononuclear cells were separated by density centrifugation over 1.5 ml of Ficoll-Paque media (MACS Miltenyi Biotec) at 400 g for 30 min at −20 °C in a swinging bucket rotor without brake. The mononuclear cell layer was collected and washed twice with PBS. The resulted pellets were stored at −80 °C for RNA isolation.
Real time PCR
As previously described24, total RNA was extracted with Trizol reagent (Qiagen), and 2 μg RNA was reversely transcribed into cDNA using cDNA synthesis kit (Life Technologies). Quantitative PCR was performed with ABI 7700 system in a SYBR Green Master Mix (Bio-Rad) containing 1 μl of cDNA and 250 nM of primers (Table 1) on the condition: 95 °C for 30 sec; 95 °C for 15 sec and 60 °C for 30 sec with 30 cycles. Expression values were expressed as 2−ΔCT using the comparative cycle threshold (CT), and normalized to the house keeping gene β-actin. Data are shown as the fold change.
Immunoblot and immunoprecipitation assay
Total cellular protein was isolated using RIPA buffer (150 mM NaCl, 1% NP-40, 0.1% SDS, 0.5% DOC, 50 mM Tris-HCl pH7.4, 15% glycerol) supplemented with protease and phosphatase inhibitor cocktail (Roche). Equal amount of the denatured protein was separated by 7.5 or 12.5% SDS-PAGE and blotted onto nitrocellulose membrane (Thermo Scientific). Membranes were rinsed once with Tris-buffered saline containing 0.05% Tween-20 (TTBS), and then blocked for 1 h in 5% BSA/TTBS. Thereafter, blots were incubated with the indicated primary antibodies at 4 °C for overnight following by HRP-conjugated goat anti-rabbit or mouse antibody for 1 h at room temperature, and developed with an enhance ECL system (Pierce). The house keeping gene GAPDH and β-actin was used as the loading control. The specific band was scanned and quantified with Image J 1.4.
Immunoprecipitation was used to assess the interaction of PKC and Rack1. Briefly, 300 μg of total cellular protein was incubated with 2 μg of rabbit anti-Rack1 antibody or mouse anti-PKCα antibody for overnight in cold room. Protein A sepharose (40 μl; Sigma) was then added and incubated for 1 hr. After 5 washes with lysis buffer, 20 μl of 2x Laemmli loading buffer was added to the pelleted Protein A sepharose and boiled for 5min. The supernatant was collected for immunoblot with the indicated antibodies.
PKC kinase activity
Cell pellets were resuspended in three times volume of lysis buffer (20 mM MOPS, 5 mM EGTA, 2 mM EDTA, 1% NP40, 50 mM β-glycerolphosphate, 50 mM sodium fluoride, 1 mM sodium vanadate, 1 mM dithiothreitol, and 1 mM benzamidine) supplemented with 1 mM phenylmethane-14 sulphonylfluoride and 10 μg/mL leupeptin and aprotinin, and incubated for 10min on ice. Total cellular protein was fractioned by centrifugation at 12000rpm, 4 °C for 20 min. A total of 50 μg protein was used to measure the PKC activity according to manufacturer’s instructions (Abcam). Briefly, 50 μg protein was adjusted to 30 μl with lysis buffer, and was added to PKC Substrate Microtiter Plate. Kinase Assay Dilution Buffer was used as Blank control. 10 μl of ATP (1 mg/ml) was then added to each well, and incubated at 30 oC for 2 h. Wells were emptied, 40 μl of the Phosphospecific Substrate Antibody was added and incubated at room temperature for 1 h. Four washes were performed with 100 μl of 1x Washing Buffer. Then, 40 μl of the diluted Anti-Rabbit IgG:HRP Conjugate (1:1000) was added to each well, and incubated at room temperature for 30 min. after 4 washes, 60 μl of the TMB Substrate was added, and incubated for 45 min. Finally, 20 μl of the Stop Solution was added. The absorbance was measured at 450 nm with Microplate reader. The PKC kinase activity was expressed by the value of OD450.
Statistical Analysis
Statistical analysis was performed by using one-way ANOVA with Tukey’s multiple comparison test for multiple time-points comparison, or 2-way ANOVA with Sidak’s multiple comparison test for multiple groups comparison (Prism 4.0, GraphPad). Results are presented as the mean ± SD. A p < 0.05 was regarded as significant difference.
Additional Information
How to cite this article: Lei, J. et al. Increased PKCα activity by Rack1 overexpression is responsible for chemotherapy resistance in T-cell acute lymphoblastic leukemia-derived cell line. Sci. Rep. 6, 33717; doi: 10.1038/srep33717 (2016).
References
Hunger, S. P. & Mullighan, C. G. Acute Lymphoblastic Leukemia in Children. N. Engl. J. Med. 373, 1541–1552 (2015).
Van Vlierberghe, P. & Ferrando, A. The molecular basis of T cell acute lymphoblastic leukemia. J. Clin. Invest. 122, 3398–3406 (2012).
Roti, G. & Stegmaier, K. New Approaches to Target T-ALL. Front Oncol. 4, 170 (2014).
Li, J. J. & Xie, D. RACK1, a versatile hub in cancer. Oncogene. 34, 1890–1898 (2015).
Guo, Y. et al. Receptor for activated C kinase 1 promotes hepatocellular carcinoma growth by enhancing mitogen activated protein kinase kinase 7 activity. Hepatology. 57, 140–151 (2013).
Ruan, Y. et al. Ribosomal RACK1 promotes chemoresistance and growth in human hepatocellular carcinoma. J. Clin. Invest. 122, 2554–2566 (2012).
Wu, J. et al. RACK1 promotes the proliferation, migration and invasion capacity of mouse hepatocellular carcinoma cell line in vitro probably by PI3K/Rac1 signaling pathway. Biomed. Pharmacother. 67, 313–319 (2013).
Subauste, M. C. et al. RACK1 downregulates levels of the pro-apoptotic protein Fem1b in apoptosis-resistant colon cancer cells. Cancer Biol. Ther. 8, 2297–2305 (2009).
Zhang, D. et al. RACK1 promotes the proliferation of THP1 acute myeloid leukemia cells. Mol. Cell Biochem. 384, 197–202 (2013).
Link, A. J. et al. Direct analysis of protein complexes using mass spectrometry. Nat Biotechnol. 17, 676–682 (1999).
Kazi, J. U., Kabir, N. N. & Rönnstrand, L. Protein kinase C (PKC) as a drug target in chronic lymphocytic leukemia. Med. Oncol. 30, 757 (2013).
Ron, D. et al. Cloning of an intracellular receptor for protein kinase C: a homolog of the beta subunit of G proteins. Proc. Natl. Acad. Sci. USA 91, 839–843 (1994).
Rosdahl, J. A., Mourton, T. L. & Brady-Kalnay, S. M. Protein kinase C delta (PKCdelta) is required for protein tyrosine phosphatase mu (PTPmu)-dependent neurite outgrowth. Mol. Cell Neurosci. 19, 292–306 (2002).
Hermanto, U., Zong, C. S., Li, W. & Wang, L. H. RACK1, an insulin-like growth factor I (IGF-I) receptor-interacting protein, modulates IGF-I-dependent integrin signaling and promotes cell spreading and contact with extracellular matrix. Mol. Cell Biol. 22, 2345–2365 (2002).
Ron, D. et al. Coordinated movement of RACK1 with activated betaIIPKC. J. Biol. Chem. 274, 27039–27046 (1999).
Jiffar, T. et al. PKC alpha mediates chemoresistance in acute lymphoblastic leukemia through effects on Bcl2 phosphorylation. Leukemia. 18, 505–512 (2004).
Mourtada-Maarabouni, M., Kirkham, L., Farzaneh, F. & Williams, G. T. Functional expression cloning reveals a central role for the receptor for activated protein kinase C 1 (RACK1) in T cell apoptosis. J. Leukoc. Biol. 78, 503–514 (2005).
Ventura-Holman, T. & Maher, J. F. Sequence, organization and expression of human FEM1B gene. Biochem. Biophy. Res. Comm. 267, 317–320 (2000).
Chan, S. L., Yee, K. S. Y., Tan, K. M. L. & Yu, V. C. The Caenorhabditis elegans sex etermination protein is a CED-3 substrate that associates with CED-4 and mediates apoptosis in mammalian cells. J. Biol. Chem. 275, 17925–17928 (2000).
Inayat-Hussain, S. H. et al. RACK-1 overexpression protects against goniothalamin-induced cell death. Toxicol. Lett. 191, 118–122 (2009).
Chen, S. et al. RACK1 regulates directional cell migration by acting on G betagamma at the interface with its effectors PLC beta and PI3K gamma. Mol. Biol. Cell. 19, 3909–3922 (2008).
Shi, Y. Mechanical aspects of apoptosome assembly. Curr. Opin. Cell Biol. 18, 677–684 (2006).
Hsieh, Y. H. et al. p38 mitogen-activated protein kinase pathway is involved in protein kinase Calpha-regulated invasion in human hepatocellular carcinoma cells. Cancer Res. 67, 4320–4327 (2007).
Yu, L. et al. Smad3/Nox4-mediated mitochondrial dysfunction plays a crucial role in puromycin aminonucleoside-induced podocyte damage. Cell. Signal. 26, 2979–2991 (2014).
Author information
Authors and Affiliations
Contributions
J.L. performed all the experiments, drafted the manuscript and revised the manuscript. Q.L., Y.G. and L.Z. participated in certain experiments. Y.L. acted as the corresponding author, designed the study and revised the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Rights and permissions
This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
About this article
Cite this article
Lei, J., Li, Q., Gao, Y. et al. Increased PKCα activity by Rack1 overexpression is responsible for chemotherapy resistance in T-cell acute lymphoblastic leukemia-derived cell line. Sci Rep 6, 33717 (2016). https://doi.org/10.1038/srep33717
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/srep33717
This article is cited by
-
Rack1 mediates tyrosine phosphorylation of Anxa2 by Src and promotes invasion and metastasis in drug-resistant breast cancer cells
Breast Cancer Research (2019)
-
Rack1 mediates Src binding to drug transporter P-glycoprotein and modulates its activity through regulating Caveolin-1 phosphorylation in breast cancer cells
Cell Death & Disease (2019)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.